Thyrotropin Alfa-Rch
Recommended EndocrinologyAuthority RequiredNot applicable line
Therapeutic use in post-thyroidectomy patients without known metastatic disease, maintained on hormone suppression therapy, for ablation of thyroid remnant tissue in combination with radioactive iodine.
1
Submissions
2006–06
On the record
$15k–45k
ICER range
1 sourced ICER · 2006
ICER stated
Cost basis
Access path
- Jul 2006Recommended
vs withholding or withdrawal of thyroid hormone therapy for…
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Preliminary economic evaluation in Pre-PBAC response; modelled base case ICER was $17,331–$17,625/QALY with sensitivity analyses $9,535–$28,101.
The PBAC noted that the presentation in the submission of preliminary economic evaluation in the form of a cost-comparison did not allow for the impact of modelling to be easily assessed. PBAC · 2006
Decision context
PopulationPost-thyroidectomy patients aged 18 years and older without known metastatic disease, maintained on hormone suppression therapy, undergoing radioactive iodine ablation of thyroid remnant tissue.
Why it was knocked back
- uncertain quality of life improvement, uncertain cost-effectiveness, inadequate evidence for reduced hospital stay claim, sensitivity of ICER to radioactive bed stay costs
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2006 | Recommended | withholding or withdrawal of thyroid hormone therapy for 4–6 weeks prior to radioiodine ablation | $15k–45k | RCT |